Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 7NIH 6INDUSTRY 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma 44Breast Neoplasms 26Sarcoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Burkitt Lymphoma 14Neuroblastoma 13Hodgkin Disease 13Leukemia 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 8Wilms Tumor 7Sarcoma, Synovial 7Neurofibrosarcoma 7Leiomyosarcoma 7Histiocytoma, Malignant Fibrous 7Hemangiosarcoma 7Fibrosarcoma 7Endometrial Neoplasms 7Urinary Bladder Neoplasms 6Multiple Myeloma 6Malignant mesenchymal tumor 6Liposarcoma 6Rhabdomyosarcoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Kidney Neoplasms 5Hemangiopericytoma, Malignant 5Waldenstrom Macroglobulinemia 4Sarcoma, Alveolar Soft Part 4

Interventions

Paclitaxel 15Carboplatin 15Taxes 9Cisplatin 8Topotecan 4Docetaxel 4Filgrastim 3pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Methods 2Gemcitabine 2GEN-1 2Etoposide 2Erlotinib Hydrochloride 2Educational Status 2Early Intervention, Educational 2Chemotherapy, Adjuvant 2vandetanib 1rilotumumab 1oregovomab 1motesanib diphosphate 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1VTX-2337 1Trabectedin 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Fallopian Tube Neoplasms × Doxorubicin × Clear all
NCT01489371 2019-03-12

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 1 Completed
16 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡